178 related articles for article (PubMed ID: 25611586)
21. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
Yip TC; Chan HL; Wong VW; Tse YK; Lam KL; Wong GL
J Hepatol; 2017 Nov; 67(5):902-908. PubMed ID: 28652084
[TBL] [Abstract][Full Text] [Related]
22. The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B.
Wong GL; Chan HL; Yuen BW; Tse YK; Luk HW; Yip TC; Hui VW; Liang LY; Lee HW; Lui GC; Wong VW
Liver Int; 2020 Mar; 40(3):549-557. PubMed ID: 31845462
[TBL] [Abstract][Full Text] [Related]
23. Quantification of hepatitis B surface antigen can help predict spontaneous hepatitis B surface antigen seroclearance.
Arai M; Togo S; Kanda T; Fujiwara K; Imazeki F; Yokosuka O
Eur J Gastroenterol Hepatol; 2012 Apr; 24(4):414-8. PubMed ID: 22273987
[TBL] [Abstract][Full Text] [Related]
24. [HBsAg seroclearance: prognostic value for the response to treatment and the long-term outcome].
Moucari R; Marcellin P
Gastroenterol Clin Biol; 2010 Sep; 34 Suppl 2():S119-25. PubMed ID: 21095515
[TBL] [Abstract][Full Text] [Related]
25. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
[TBL] [Abstract][Full Text] [Related]
26. Distinct seromarkers predict different milestones of chronic hepatitis B progression.
Liu J; Yang HI; Lee MH; Batrla-Utermann R; Jen CL; Lu SN; Wang LY; You SL; Hsiao CK; Chen CJ;
Hepatology; 2014 Jul; 60(1):77-86. PubMed ID: 24700432
[TBL] [Abstract][Full Text] [Related]
27. [Clinical characteristics and effect of secondary individualized therapy in chronic hepatitis B patients infected with the rtA181 mutation hepatitis B virus].
Ji FZ; Wang L; Yang BH; Zhao JJ; Liu F; Xue Y; Li T
Zhonghua Gan Zang Bing Za Zhi; 2012 Apr; 20(4):280-4. PubMed ID: 22964149
[TBL] [Abstract][Full Text] [Related]
28. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment.
Chen CH; Lu SN; Hung CH; Wang JH; Hu TH; Changchien CS; Lee CM
J Hepatol; 2014 Sep; 61(3):515-22. PubMed ID: 24798617
[TBL] [Abstract][Full Text] [Related]
29. Multiple doses of hepatitis B recombinant vaccine for chronic hepatitis B patients with low surface antigen levels: a pilot study.
Lai MW; Hsu CW; Lin CL; Chien RN; Lin WR; Chang CS; Liang KH; Yeh CT
Hepatol Int; 2018 Sep; 12(5):456-464. PubMed ID: 30088198
[TBL] [Abstract][Full Text] [Related]
30. Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.
Boglione L; Cardellino CS; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
J Med Virol; 2014 Nov; 86(11):1845-50. PubMed ID: 25131947
[TBL] [Abstract][Full Text] [Related]
31. Emerging pipeline drugs for hepatitis B infection.
Cox N; Tillmann H
Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605
[TBL] [Abstract][Full Text] [Related]
32. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.
Chevaliez S; Hézode C; Bahrami S; Grare M; Pawlotsky JM
J Hepatol; 2013 Apr; 58(4):676-83. PubMed ID: 23219442
[TBL] [Abstract][Full Text] [Related]
33. [Changes of serum HBsAg in HBeAg positive chronic hepatitis patients with sustained viral response to long-term lamivudine treatment].
Chen JJ; Wang ZH; Ma SW; Chen YP; Peng J; Guo YB; Hou JL
Zhonghua Gan Zang Bing Za Zhi; 2008 Jun; 16(6):416-20. PubMed ID: 18578990
[TBL] [Abstract][Full Text] [Related]
34. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.
Yuen MF; Wong DK; Sablon E; Tse E; Ng IO; Yuan HJ; Siu CW; Sander TJ; Bourne EJ; Hall JG; Condreay LD; Lai CL
Hepatology; 2004 Jun; 39(6):1694-701. PubMed ID: 15185311
[TBL] [Abstract][Full Text] [Related]
35. Long-term efficacy of interferon alpha therapy on hepatitis B viral replication in patients with chronic hepatitis B: a meta-analysis.
Yang YF; Zhao W; Xia HM; Zhong YD; Huang P; Wen J
Antiviral Res; 2010 Feb; 85(2):361-5. PubMed ID: 19900483
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy of chronic hepatitis B by anti HBV vaccine.
Pol S; Couillin I; Michel ML; Driss F; Nalpas B; Carnot F; Berthelot P; Bréchot C
Acta Gastroenterol Belg; 1998; 61(2):228-33. PubMed ID: 9658616
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine.
Vandepapelière P; Lau GK; Leroux-Roels G; Horsmans Y; Gane E; Tawandee T; Merican MI; Win KM; Trepo C; Cooksley G; Wettendorff M; Ferrari C;
Vaccine; 2007 Dec; 25(51):8585-97. PubMed ID: 18031872
[TBL] [Abstract][Full Text] [Related]
38. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
39. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
[TBL] [Abstract][Full Text] [Related]
40. Kinetics of serum HBsAg in Chinese patients with chronic HBV infection with long-term adefovir dipivoxil treatment.
Li M; Xi H; Wang Q; Hou F; Huo N; Zhang X; Li F; Xu X
Chin Med J (Engl); 2014; 127(11):2101-4. PubMed ID: 24890161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
